Acute liver failure (ALF) occurs when an acute injury to the liver is not compensated by the liver’s endogenous regenerative capacity, resulting in impaired liver function. Accelerating the liver’s regenerative capacity by activating the MET-hepatocyte growth factor (HGF) signaling pathway was the aim of this research. AGMB-101, developed by Agomab Therapeutics NV, is an agonist antibody targeting MET that was tested in two murine models of ALF.

Researchers from Sutro Biopharma Inc. presented the discovery and preclinical characterization of a novel receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeted antibody-drug conjugate (ADC), STRO-003, being developed for the treatment of cancer.

The Institute of Cancer Research (ICR) in London is shifting the focus of drug discovery from molecular targets in cancer cells to take in the whole ecosystem supporting tumor growth, evolution and the development of resistance. The aim is to exploit new understanding of the way cancers evolve within the ecosystem of the body, the interaction between cancer cells and the immune system, and the reliance of a tumor on the tissue and growth signals that surround it. Manipulating this environment could make cancer cells become “extinct,” ICR researchers say.

A combination of radiation therapy and CD47 blockade induced an abscopal effect in animal studies even in animals that lacked T cells, researchers reported in the Nov. 21, 2022, online issue of Nature Cancer. The findings are “the first demonstration of T-cell-independent abscopal response,” co-corresponding author Edward Graves told BioWorld. “We’re not trying to say that all abscopal responses are macrophage-mediated. There are plenty that require T cells,” Graves clarified. But “there is another avenue of abscopal responses that has not been reported. ... All the abscopal literature is about stimulating an adaptive response.”